Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Tukysa (tucatinib)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Pfizer

Drug class:

HER2 inhibitor

Related drugs:

‹

trastuzumab biosimilar (0)

trastuzumab (407)

lapatinib (107)

neratinib (102)

trastuzumab-pkrb (24)

margetuximab-cmkb (18)

poziotinib (17)

zenocutuzumab-zbco (16)

mobocertinib (12)

trastuzumab-dttb (11)

zanidatamab-hrii (11)

trastuzumab-strf (9)

trastuzumab-anns (9)

trastuzumab-dkst (9)

trastuzumab-qyyp (9)

Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T (4)

pertuzumab/trastuzumab/hyaluronidase-zzxf (3)

sunvozertinib (3)

trastuzumab/hyaluronidase-oysk (2)

JBJ-08–178–01 (2)

Hercease (trastuzumab biosimilar) (1)

HERtiCAD (trastuzumab biosimilar) (1)

Hervelous (trastuzumab biosimilar) (1)

EG12014 (trastuzumab biosimilar) (1)

sevabertinib (1)

TX05 (trastuzumab biosimilar) (1)

ALT02 (trastuzumab biosimilar) (0)

trastuzumab biosimilar (AP062) (0)

DA 3111 (trastuzumab biosimilar) (0)

HER-2/neu peptide vaccine (0)

HER2 t-haNK (0)

Hervycta (trastuzumab biosimilar) (0)

JNJ-26483327 (0)

diznalimgene lisbac (0)

MVA-BN-HER2 (0)

NeuCeptin (trastuzumab biosimilar) (0)

nelipepimut-S (0)

lapuleucel-T (0)

pertuzumab-dpzb (0)

ertumaxomab (0)

trastuzumab biosimilar (SIBP-01) (0)

TAC100-HER2 (0)

glycooptimized trastuzumab-GEX (0)

TrastuRel (trastuzumab biosimilar) (0)

Undisclosed HER2Bi-armed ATC (0)

trastuzumab biosimilar (0)

trastuzumab biosimilar (0)

›

HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	trastuzumab + tucatinib Sensitive: A1 - Approval trastuzumab + tucatinib Sensitive : A1	trastuzumab + tucatinib Sensitive: A1 - Approval trastuzumab + tucatinib Sensitive : A1
RAS wild-type + HER-2 positive	Colorectal Cancer	RAS wild-type + HER-2 positive	Colorectal Cancer	trastuzumab + tucatinib Sensitive: A1 - Approval trastuzumab + tucatinib Sensitive : A1	trastuzumab + tucatinib Sensitive: A1 - Approval trastuzumab + tucatinib Sensitive : A1
HER-2 amplification + RAS wild-type + BRAF wild-type	Colon Cancer	HER-2 amplification + RAS wild-type + BRAF wild-type	Colon Cancer	trastuzumab + tucatinib Sensitive: A2 - Guideline trastuzumab + tucatinib Sensitive : A2	trastuzumab + tucatinib Sensitive: A2 - Guideline trastuzumab + tucatinib Sensitive : A2
HER-2 amplification + RAS wild-type + BRAF wild-type	Rectal Cancer	HER-2 amplification + RAS wild-type + BRAF wild-type	Rectal Cancer	trastuzumab + tucatinib Sensitive: A2 - Guideline trastuzumab + tucatinib Sensitive : A2	trastuzumab + tucatinib Sensitive: A2 - Guideline trastuzumab + tucatinib Sensitive : A2
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	tucatinib Sensitive: B - Late Trials tucatinib Sensitive : B	tucatinib Sensitive: B - Late Trials tucatinib Sensitive : B
HER-2 positive	Colorectal Cancer	HER-2 positive	Colorectal Cancer	trastuzumab + tucatinib Sensitive: B - Late Trials trastuzumab + tucatinib Sensitive : B	trastuzumab + tucatinib Sensitive: B - Late Trials trastuzumab + tucatinib Sensitive : B
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	ado-trastuzumab emtansine + tucatinib Sensitive: B - Late Trials ado-trastuzumab emtansine + tucatinib Sensitive : B	ado-trastuzumab emtansine + tucatinib Sensitive: B - Late Trials ado-trastuzumab emtansine + tucatinib Sensitive : B
HER-2 positive	Biliary Tract Cancer	HER-2 positive	Biliary Tract Cancer	trastuzumab + tucatinib Sensitive: C1 - Off-label trastuzumab + tucatinib Sensitive : C1	trastuzumab + tucatinib Sensitive: C1 - Off-label trastuzumab + tucatinib Sensitive : C1
HER-2 amplification	Breast Cancer	HER-2 amplification	Breast Cancer	tucatinib Sensitive: C2 – Inclusion Criteria tucatinib Sensitive : C2	tucatinib Sensitive: C2 – Inclusion Criteria tucatinib Sensitive : C2
HER-2 amplification	Breast Cancer	HER-2 amplification	Breast Cancer	trastuzumab + tucatinib Sensitive: C2 – Inclusion Criteria trastuzumab + tucatinib Sensitive : C2	trastuzumab + tucatinib Sensitive: C2 – Inclusion Criteria trastuzumab + tucatinib Sensitive : C2
HER-2 expression	Colorectal Cancer	HER-2 expression	Colorectal Cancer	trastuzumab + tucatinib Sensitive: C3 – Early Trials trastuzumab + tucatinib Sensitive : C3	trastuzumab + tucatinib Sensitive: C3 – Early Trials trastuzumab + tucatinib Sensitive : C3
HR positive	HER2 Positive Breast Cancer	HR positive	HER2 Positive Breast Cancer	palbociclib + tucatinib Sensitive: C3 – Early Trials palbociclib + tucatinib Sensitive : C3	palbociclib + tucatinib Sensitive: C3 – Early Trials palbociclib + tucatinib Sensitive : C3